Nobio

Company Overview

Snapshot

Founded in July 2015 by Ervin Weiss, Nobio operates with 11–50 employees. The company has secured funding across 4 rounds from 2 investors, including aMoon Fund. A significant milestone was achieved in September 2021 when its infinix Antibacterial Composites were recognized as a 2021 Best of Class Technology Award winner.

Business overview

Nobio develops long-term antibacterial and antiviral solutions for medical, dental, and consumer products. The company's core technology involves extremely potent particles covered with a high concentration of highly active antimicrobial molecules that effectively kill a wide range of microorganisms on contact. These particles can be permanently embedded in or used as a coating on various products and materials, providing powerful bioprotection. Nobio commercializes its technology through its own products, such as the Infinix line for dental fillings, and through partnerships with industry leaders, serving markets in healthcare, dental, and consumer goods.

Strategic signal

In September 2021, Nobio's infinix Antibacterial Composites received the 2021 Best of Class Technology Award. This recognition highlights the clinical importance of Infinix in preventing demineralization and reducing restoration failure due to secondary caries, signaling strong validation of Nobio's patented antimicrobial particle technology within the dental industry and its potential for broader application in material sciences.

Company Intelligence Q&A

What was a key recognition for Nobio's dental products?

In September 2021, Nobio's infinix Antibacterial Composites were recognized as a 2021 Best of Class Technology Award winner for their role in preventing demineralization and reducing restoration failure in dental applications.

When did Nobio receive FDA clearance for its dental composites?

In September 2020, Nobio received FDA 510(k) clearance for its Infinix family of dental composites, which significantly reduce tooth demineralization by inhibiting bacterial growth.

Did Nobio receive any grants for COVID-19 related initiatives?

In April 2020, Nobio secured a grant from the Israel Innovation Authority to develop and manufacture innovative solutions for managing the COVID-19 outbreak, focusing on personal protective equipment (PPE) and long-acting surface coatings.

When did Nobio receive FDA approval for its antibacterial dental fillings?

In August 2019, Nobio received FDA approval to market its antibacterial material for dental fillings, granting the company access to the dental materials market.

Which investors participated in Nobio's August 2018 funding round?

In August 2018, Nobio secured funding from investors including aMoon Fund and Dr. Ole Jensen.